Multiple Sclerosis Patients Treated with Diroximel Fumarate in the Real-World Setting have High Rates of Persistence and Adherence

被引：0
|
作者：
Liseno, Jacob [1 ]
Lager, Brittney [1 ]
Miller, Catherine [2 ]
Shankar, Sai L. [2 ]
Mendoza, Jason P. [2 ]
Lewin, James B. [2 ]
机构：
[1] AcariaHealth, Orlando, FL USA
[2] Biogen, Cambridge, MA USA
来源：
NEUROLOGY | 2021年 / 96卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
2027
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Real-World Persistence with Ocrelizumab in Multiple Sclerosis: a Systematic Review
    Petrie, John L.
    Smith, Charlie A.
    Fountain, Donna
    Machnicki, Gerardo
    NEUROLOGY AND THERAPY, 2024, 13 (06) : 1597 - 1605
  • [32] The potential of individualized patient coaching to optimize treatment with delayed-release dimethyl fumarate: a retrospective analysis of patients with multiple sclerosis treated in a real-world setting
    Begus-Nahrmann, Y.
    Niemczyk, G.
    Schmid, B.
    Maeurer, M.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 636 - 637
  • [33] Serum Neurofilament Light Chain as Biomarker for Cladribine-Treated Multiple Sclerosis Patients in a Real-World Setting
    Seiberl, Michael
    Feige, Julia
    Hilpold, Patrick
    Hitzl, Wolfgang
    Machegger, Lukas
    Buchmann, Arabella
    Khalil, Michael
    Trinka, Eugen
    Harrer, Andrea
    Wipfler, Peter
    Moser, Tobias
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (04)
  • [34] A Retrospective Analysis of Real-World Discontinuation Rates with Delayed-Release Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis
    Michelle Allan
    Lindsay Grant
    Neurology and Therapy, 2020, 9 : 85 - 92
  • [35] Real-world use of cladribine tablets (Completion rates and treatment persistence) In patients with multiple sclerosis in England: the CLARENCE Study
    Brownlee, W.
    Amin, A.
    Ashton, L.
    Herbert, A.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 666 - 667
  • [36] Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: The CLARENCE study
    Brownlee, Wallace
    Amin, Amerah
    Ashton, Luke
    Herbert, Alex
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 79
  • [37] Effectiveness and safety of dimethyl fumarate treatment in relapsing multiple sclerosis patients: Real-world evidence
    Alroughani R.
    Ahmed S.F.
    Behbehani R.
    Al-Hashel J.
    Neurology and Therapy, 2017, 6 (2) : 189 - 196
  • [38] Effectiveness and safety of dimethyl fumarate treatment in patients with relapsing multiple sclerosis: A real-world evidence
    Alroughani, Raed
    Ahmed, Samar
    Behbehani, Raed
    Al-hashel, Jasem
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (02) : NP17 - NP17
  • [39] LymphoTEC: a Retrospective Real-World Study on Lymphocyte Reconstitution After Lymphopenia in Patients with Multiple Sclerosis Treated with Dimethyl Fumarate in France
    de Seze, Jerome
    Labauge, Pierre
    Liblau, Roland
    Martinez, Mikel
    Moreau, Thibault
    Suchet, Laurent
    Vermersch, Patrick
    Vukusic, Sandra
    Mathey, Guillaume
    Michel, Laure
    Ciron, Jonathan
    Ruet, Aurelie
    Maillart, Elisabeth
    Zephir, Helene
    Papeix, Caroline
    Defer, Gilles
    Cohen, Mikael
    Laplaud, David Axel
    Berger, Eric
    Clavelou, Pierre
    Thouvenot, Eric
    Heinzlef, Olivier
    Pelletier, Jean
    Giannesini, Claire
    Casez, Olivier
    Bourre, Bertrand
    Wahab, Abir
    Magy, Laurent
    Camdessanche, Jean-Philippe
    Doghri, Ines
    Labeyrie, Celine
    Hankiewicz, Karolina
    Neau, Jean-Philippe
    Pottier, Corinne
    Dobay, Pamela
    Li, Hanyue
    Levin, Seth
    Gros, Marilyn
    Ruiz, Marta
    Rollot, Fabien
    ADVANCES IN THERAPY, 2025, : 1760 - 1782
  • [40] Real-World Assessment of Adherence and Persistence to Second-Line Disease-Modifying Therapies among Multiple Sclerosis Patients
    Halpern, Rachel
    Agarwal, Sonalee
    Borton, Leigh A.
    Babic, Tomislav
    NEUROLOGY, 2010, 74 (09) : A548 - A549
12345